NR4A2 and synucleinopathy: The finding that α-SYN aggregates reduce the dopaminergic phenotype by GSK-3-mediated degradation of NURR1 suggests that GSK-3 inhibitors might be a therapeutic option to preserve the nigrostriatal track in synucleinopathies such as Parkinson’s disease.